Boardroom Alpha
Meeting calendar
NUTX · Annual meeting · Monday, July 14, 2025

Nutex Health Inc

7 nominees · 5 ballot items.

Election of directors; advisory say-on-pay; amendment to equity incentive plan increasing shares and evergreen increases; ratification of Grant Thornton LLP as independent auditor; and other business as may be properly brought before the meeting.

Market cap
$1.3B
1Y TSR
+11.7%
Board grade
C
Record date
May 22, 2025
Filing
DEF 14A
Meeting concluded · Jul 14, 2025

Follow how the vote landed and what changed on Nutex Health Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Re-elect six current directors and elect Frank E. Jaumot as a new independent director to serve a one-year term ending at the 2026 annual meeting.

  2. 2

    Advisory Vote on the Compensation of Our Named Executive Officers

    ManagementBoard: FOR

    Advisory, non-binding vote on the compensation of Nutex Health Inc.’s named executive officers as disclosed in this proxy statement.

  3. 3

    Amendment to the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan

    ManagementBoard: FOR

    Increase the number of shares available for issuance under the 2023 Plan by 1,100,000 and provide for automatic annual increases of 5% of outstanding shares (subject to board discretion to reduce or stop increases).

  4. 4

    Ratification of the Appointment of Grant Thornton LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2025

    ManagementBoard: FOR

    Ratify the appointment of Grant Thornton LLP as Nutex Health Inc.’s independent registered public accounting firm for 2025. The Audit Committee will reconsider if not ratified; board recommends FOR.

  5. 5

    Other Matters

    ManagementBoard: FOR

    To consider and vote upon such other business as may properly be brought before the Annual Meeting or any adjournments or postponements thereof.

Director elections

Nominees on the ballot7

Not independent
Tenure on this board
4.3 yrs
Also a director at
Cardio Diagnostics Holdings Inc (CDIO)General Purpose Acquisition Corp (GPAC)Veraxa Biotech Holding AG (VRXA)
Michael L. Reed, MPH
Independent
Tenure on this board
New nominee
Scott J. Saunders, MPPM
Independent
Tenure on this board
New nominee
Ownership

Top institutional holders10

Latest 13F quarter
1Pertento Partners LLP5.4%373,970$36M
2VANGUARD CAPITAL MANAGEMENT LLC3.2%219,131$21M
3AMERICAN CENTURY COMPANIES INC3.0%203,450$19M
4BlackRock, Inc.2.8%190,823$18M
5Topline Capital Management, LLC2.6%177,800$17M
6BlackRock, Inc.2.2%151,848$14M
7STATE STREET CORP1.8%123,177$12M
8GEODE CAPITAL MANAGEMENT, LLC1.5%104,021$10M
9MILLENNIUM MANAGEMENT LLC1.3%89,571$9M
10UBS Group AG1.0%66,670$6M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Nutex Health Inc 2025 annual meeting?
Nutex Health Inc (NUTX) holds its 2025 annual shareholder meeting on Monday, July 14, 2025.
What is the record date for the Nutex Health Inc 2025 meeting?
The record date for the Nutex Health Inc 2025 meeting is Thursday, May 22, 2025. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Nutex Health Inc's 2025 meeting?
The board is presenting 7 director nominees at the Nutex Health Inc 2025 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Nutex Health Inc 2025 meeting?
Shareholders will vote on 5 proposals at the Nutex Health Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer